International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

A Review Work on Sustained Matrix Tablet Study

Lovely Chaurasia[1]-*Department of Pharmacy, IIMT College of medical sciences, IIMT University Meerut 250001, Uttar Pradesh, India*

Nishant kumar*[1] *(Research Scholar) Department of Pharmacy, IIMT College of medical sciences, IIMT University Meerut 250001, Uttar Pradesh, India*

Deeksha kumari[2] *Department of Pharmacy, IIMT College of medical sciences, IIMT University Meerut 250001, Uttar Pradesh, India*

Dr. Prabhakar Vishvkarma[3]-*Department of Pharmacy, IIMT College of medical sciences, IIMT University Meerut 250001, Uttar Pradesh, India*

Date of Submission: 01-08-2023 Date of Acceptance: 13-08-2023

Abstract

Formulations that enable the medicine to be released gradually over a longer period of time are very useful for the treatment of chronic illnesses.

Matrix tablets have been determined to be the kind of prolonged drug release that has the highest probability of being successful when taken orally as a mode of delivery. Matrix tablets maintain both the steady state of the concentration of the medication in the plasma as well as the steady state of the rate at which the drug is released for the whole of the treatment period. Because of this, the pills are able to exert their therapeutic effect over a much longer length of time. When treating conditions that need frequent dosage yet have a short half-life, it is very necessary to adopt formulations that allow for longer drug release. It's possible that the matrix can govern how quickly the medicine is distributed throughout the system. The usage of retardants such polyglycolic acid, polymethyl methacrylate, and hydroxypropyl methylcellulose (HPMC) is something that is considered to be standard procedure. It is possible that the medication is located inside the matrix core of the retardant. The matrices that are used may be constructed of minerals, they may be hydrophobic, or they may be biodegradable. All three of these characteristics are also possible. Matrix tablets include built-in mechanisms that govern the release of medications, and they may be produced using processes such as wet granulation or direct compression. These mechanisms make use of a broad range of polymers in a number of different ways. The release of the medication from matrix tablets may be regulated using both a technique that is controlled by diffusion as well as a process that is controlled by dissolving. Matrix pills, as a result of this, improve therapeutic efficacy while simultaneously reducing the number of times a drug has to be administered and increasing patient compliance.

Keywords: Sustained release, Matrix Tablets, HPMC, Retardants, Biodegradable

I. INTRODUCTION:

Oral dosage forms that have varied release characteristics have been defined using a variety of names, such as controlled or postponed release, delayed release, repeated action, extended-release, sustained release, and other approaches. After employing standard administration methods, there is a consistent shift in the amount of medication that is present in plasma, and every method of administering drugs works to counteract this effect.

Dosages with a modified release

This term refers to prescription dosage forms that, in order to achieve therapeutic and practical goals that traditional dosage forms do not, have specific course or location characteristics for drug release. This is done in order for these dosage forms to be considered "advanced."

Controlled release

Because the medicine has a delivery rate of zero while it is being administered, the passage of time has no impact on the concentration that is being measured.

Delayed-release:

A delayed dose form is one that releases the drug gradually rather than immediately after it has been taken, rather than immediately after it has been administered.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

Extended-release:
A dosage form is referred to as extended-release if it allows for a lower dosing frequency than that provided by a standard dosage form.

Long-acting:
These medications are given in a dosage form that, in comparison to standard dosage forms, enables absorption to continue for a longer period of time.

Repeat action:
The first dose is administered as soon as possible after the food or drink has been consumed, and subsequent doses are only given on an as-needed basis.

Sustained-release:

The rate at which the medicine is absorbed into the body is directly proportional to how the medication is administered.

The best commercially accessible prolonged action medications are sustained release matrix tablets since they don't need any unique manufacturing processes, allow for huge drug doses, and don't limit the amount of drug that may be taken. [1-2]

An innovative drug delivery system (NDDS) that greatly increases the therapeutic efficacy of drugs is one that distributes them using a matrix that provides continuous drug release.

The development of new matrix-based formulations that have a sustained drug release and make use of excipients that are easily available and affordably priced is now under way. [3] The sustained-release dose type was advantageous for both the patient and the caregiver since it offered longer drug levels in plasma and frequently avoided the need for nighttime administration of the medication. This was beneficial for all parties involved.

Because of the sustained-release formulation, the medicated substance that produces the sought-after therapeutic effect is made available right away. Techniques for the delivery of medicines via the mouth that have a prolonged effect are becoming more widespread in the pharmaceutical sector.

In addition, there is a large amount of interest in the creation of a dosage form that is capable of enabling a substantial amount of drug loading, in particular for medicinal formulations that dissolve well in water. When it comes to a prolonged action formulation, matrix tablets are thought to be the dosage form that has the fewest processing variables incorporated in the mix. This is important from a financial standpoint. [4, 5]



Fig no: 1 sustained matrix tablet action[5]

The following are categories of Matrix tablets:
The following categories apply to Matrix's various tablet offerings:
According to the use of compounds that act as retardants:
This category includes the five different kinds of matrix tablets that are listed below:

- **Water-repellent matrix**
- **Lipid matrix**
- **A matrix that adores water**
- **Material biodegradable**

Hydrophobic Matrices

The term "Plastic Matrices" is often used to refer to hydrophobic matrices.Producing a sustained-release oral dosage form requires the medicine to be combined with an inert and/or water-repellent polymer via the use of this approach. After that step, the powdered form of the drug is turned into a tablet. Because of this, the drug was spread via a system of channels that are still present amid the tightly packed polymer particles. As a consequence, there was a continuous release of the medication, which is now in the process of dissolving. Polyethylene, polyvinyl chloride (PVC), and acrylate polymers, as well as their copolymers, are a few examples of hydrophobic matrices that

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

may be found in modern materials. In the procedure that controls the rate at which things occur, one of the steps involves the absorption of the fluid that is present in the matrix.

Diffusion is the mechanism that is employed for the one-of-a-kind tablet release strategy that is used by this particular drug. This medication does not use any other release mechanism. Some varieties of matrix tablets lose their capacity to perform their intended functions when they are exposed to liquids, such as water and stomach acid. [6, 7, and 8]

Lipid matrices:

For the purpose of constructing these matrices, lipid waxes and other substances with similar characteristics are used. By using mechanisms such as erosion and pore diffusion, these sorts of materials make it feasible for drugs to be distributed throughout the body in a controlled manner. When opposed to polymer matrices, which are entirely insoluble, the releasing properties are thus far more sensitive to the composition of digestive juice. This is in contrast to the fact that polymer matrices are completely insoluble.

Matrices hydrophilic

It is necessary to utilize a hydrophilic polymer in order to ensure that one or more drugs are appropriately integrated into a matrix (gelling agent). Oral controlled drug delivery makes regular use of water-loving polymer matrices because of the efficiency of these matrices in producing a desired drug release profile, the cost of these matrices, and the widespread regulatory approval of these matrices. The various types of polymers that are utilized in the building of these matrices are taken into account and are used to further categorize them into a further three categories.

Cellulose derivatives

Cellulose derivatives are the polymers that are used in the formulation. These polymers include HPMC 100, HEC, and SCMC.

Polymers that are natural or semi-synthetic and are not cellulose, including:

In the category of acrylic acid polymers, the polymer known as Carbopol-934 is the one that sees the greatest use.

Biodegradable Matrices: The constituent parts of polymers and the functional groups they form are built on a network of interdependencies. Have Fragile Connections Due to their composition of discrete elements and functional clusters, these matrices degrade with time. It is possible to digest or release these molecules after they have been physiologically broken down into oligomers and monomers, either by non-enzymatic processes or by enzymes released into the environment around living cells.

Proteins and polysaccharides are two examples of naturally occurring polymers that may be modified. [9, 10]

Material matrix

Mineral matrices may include polymers synthesized from a broad range of seaweed species. You'll find these polymers in mineral matrices. Alginic acid and other hydrophilic polysaccharides may be present in mineral matrices. Some kinds of brown seaweed may be treated with a mild alkali solution to extract this acid.

Although the drug molecules are spread throughout the matrix, the rate at which they are released is controlled by the matrix's porosity. The matrix now includes three new unique groups.

a) Structures that include macropores

The holes of this particular kind of matrix range in size from 0.1 to 1 m, which makes them much bigger than diffusion molecules. The drug is able to enter this sort of system since it can pass via these pores.

b) Methods that use micropores

Molecules of medicinal value may go through holes with diameters ranging from 50 to 200 nm.

c) Poreless or impermeable systems

These systems are completely devoid of pores. Through the pores and spaces of network meshes, molecular diffusion occurs.

These systems are completely devoid of pores. Through the pores and spaces of network meshes, molecular diffusion occurs.

There is no pore phase in the locations where the polymeric phase is present.

Justifications for the creation of the SR matrix DDS 11 include the following:

- To decrease the amount of time between doses,
- To stabilize plasma levels more consistently,
- To allow for more medication consumption,
- To have fewer adverse effects

Extended and Repeated Release Matrix Tablet Benefits:

Sustained-release formulations are less labor-intensive to produce and more efficient, economical, and adaptable. They could also be able to keep therapeutic concentrations up for longer. Finally,

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

sustained-release formulations may be used to reduce the risk of a toxic blood level. [11-15]

- In spite of this, formulations that have sustained release nevertheless have the potential to boost patient compliance. It is possible to reduce the toxicity of a drug by slowing its absorption.
- Increase the drug's stability by protecting it from the hydrolysis that occurs in the gastrointestinal system as well as any other alterations that are derived from it.
- Attempts should be made to mitigate the adverse effects both locally and systemically.
- An increase in the efficacy of the treatment.
- A reduction in the accumulation of medicine as a result of continued dosing.

POLYMERS USED IN MATRIX TABLET:

Hydrogel

Polyethylene Oxide (PEO), Cross-linked Polyvinyl pyrrolidone (PVP), Polyvinyl Alcohol (PVA), and Polyhydroxyethyl methyl acrylate are the polymers that are used in the matrix tablet.

Soluble polymers

PEG, PVA, PVP, and HPMC (HPMC) are the components.

Examples of polymers include PGA, PCL, and polyanhydrides. Polymers may also have a biological origin.

Non-biodegradable polymers

Ethylcellulose (EC), Cellulose Acetate (CA), Polyvinyl Chloride (PVC), Polyether Urethane (PEU), Polydimethylsiloxane (PDS), Polyethylene Vinyl Acetate (PVA), and Polyvinyl Chloride (PVC) are some of the materials that may be used to make plastic.

Polymers with mucoadhesive properties

- SCMC and Tragacanth.
- Natural gums
- Xanthan gum

A perfect polymer would have the following characteristics: it would be non-toxic, have a high mechanical strength, and be easy to work with. Adaptability and a wide range of properties, including those that are structural, physiological, and molecular, would also be desirable.

In addition to being inexpensive and straightforward to produce, it should also be safe for the environment and unreactive to the host's tissue.[16-20]

Several Points to Consider When Choosing Polymers:

- It must be easy to produce the polymer, and it must be soluble. The polymer must have a predetermined number of molecules, and it must be acceptable for use in a biological environment. Finally, the polymer must break down on its own in a natural way.
- It should provide a strong interaction in both the medication and the polymer.

The following characteristics make a drug appropriate for sustained-release tablet formulation:

- The extended-release pill has to meet the ideal pharmacokinetics and physiological requirements, which may be summarized as follows:
- It is required that the atomic size be lower than one thousand Dalton.
- Absorption must take place by diffusion, and neither pH nor catalysts should have any influence on the general absorbability of any GI fragment discharge.
- The half-life of the elimination process should be between 2 and 8 hours.
- Because this decreases the drugs' bioavailability, the metabolic process of drugs shouldn't take place when they are being absorbed.
- The absolute bioavailability should be at least 75%, and achieving a higher value would be preferable.

METHODS FOR THE PREPARATION OF MATRIX TABLETS

1. Wet Granulation Technique

- Milling the excipients and combining the drug, polymer, and medication together using gravity.
- Putting together the mixture for the binder.
- Wet massing, in which a granulating or binder solution is included into the process.
- The process of separating dry particles from wet ones.
- The grains are allowed to dry out.
- Screening done using dry granules.
- The tablet has been crushed. The process of creating "running powder" involves dissolving the ingredients in an emollient while swirling them.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

2. The Granulation Process Using Dry

- The grinding and stirring by gravity of the active ingredients, polymer, and inactive ingredients
- Slug or roll compaction, depending on the material
- The pulverizing and screening of powder and slugs that have been compressed.
- Destroying itself after being mixed with lubricant
- The tablet has been made into a more compact form.

3. The Sintering Process

- The formation of a powdery mass is achieved by a process known as sintering, in which neighboring particle surfaces are brought into contact with one another.
- Sintering, in its more traditional form, is accomplished by heating the solid material while maintaining a lower temperature.
- Because of the sintering process, there was a change reported in both the hardness and the time of tablet disintegration when subjected to high temperatures.
- The sintering procedure is used to make sustained release matrix tablets, which are used to maintain the stability of the medication while also delaying its release.

Design Considerations for Dosage Forms

There are two main types of components that will define the dosage form's composition. The following groups describe them well:[21-30]

1. Biological considerations

a. First-pass effect:

Drugs with a large first-pass effect tend to be released slowly. The substance's bioavailability is affected by the pace at which it is released.

b. Half-life:

The half-life of a pharmaceutical substance is the quantitative parameter used to ascertain the duration of time during which it persists inside the human organism. If the chemical exhibits a half-life of less than two hours, the administration of the dose may result in an excessively concentrated drug due to the relatively brief duration of the substance's half-life. However, when the medication is delivered at regular doses and using continuous drug delivery systems, the half-life of elimination is maintained at eight hours in the body.

c. Adverse effects:

Adverse effect is a possibility that extending the release of the medicine may lead to unintended adverse effects.

d. Absorption and solubility:

Absorption and solubility the concepts of absorbency and soluble are connected to one another. Drugs that are less water soluble might have a negative impact on the overall efficacy of the absorption process. [31-33]

e. Metabolism:

Pharmaceutical substances that undergo substantial metabolic transformations either inside the gastrointestinal tract or in the surrounding tissue before being absorbed into the bloodstream may experience a decrease in their capacity to be effectively used by the body when provided in dosage forms that release the drug at a slower rate. Despite the medication's low disintegration rate, it remains possible to develop a sustained-release dosage form for it. However, it is necessary to enhance the drug's solubility by an acceptable approach prior to commencing the formulation process. Conversely, given the systemic distribution of the medication, the occurrence of drug crystallization is seen during this temporal interval. However, it is essential to avoid this phenomenon due to its possible deleterious effects.

2. Physiochemical factors

a.Drug stability: acidic digestion and breakdown cause pharmaceutical permeability in the digestive system.

b.oral dosage formulations. Solid drugs decay slower than suspended or solution drugs. The most effective control device acts solely in the intestines. Bioavailability of a stomach-poisonous drug may be greatly increased.

c. Aqueous solubility & pKa: A drug that will absorb, dissolve, and partition into the absorbing membrane in water-phase near the delivery site. The drug's water solubility and pKa affect its absorption. These traits make controlled release methods effective. High-aqueous-solubility drugs breakdown slowly and have poor oral bioavailability.

d. Partition Coefficient: The organic phase's medicine-to-water ratio.

International Journal of Pharmaceutical research and Applications
Volume 8, Issue 4, Jul.-Aug. 2023, pp: 1617-1624 www.ijprajournal.com ISSN: 2456-4494

Drugs with higher partition co-efficients are unsuitable for oral SRDDS because they won't partition out of the phospholipid membranes. The formula determines it.

K= Co/Cw
Co = Conc. at eqm. in oil.
Cw = equilibrium water concentration.

e. Membrane cavity shape and molecule size impact diffusivity

The flexible polymer array helps intermediate molecular weight pharmaceuticals diffuse at 100–400 Daltons, or 10–6–10–9 cm2/sec. Many polymers have diffusion coefficients below 10–12 cm2/sec for medicines above 500 Daltons. Proteins and peptides are difficult to dose-control. [34-35]

EVALUATION OF TABLETS DESIGNED FOR EXTENDED RELEASE:

In order to assure the durability, safety, stability, and dependability of a product with prolonged release, it is essential to conduct in vitro-in vivo correlation (IVIVC) research and establish a strong connection between these two aspects. The establishment of a link between the two entities is also necessary.

Extensive research has been conducted on the following criteria for assessment:

1. Techniques performed in vitro

a. Beakertechnique b. Rotatingdisc procedure c. RotatingBottle technique d. RotatingBasket method e. StationaryBasket technique f. Oscillatingtube process g. Dialysisprocess h. USPdissolution technique.

2. In–vivo Methods

Following the completion of the necessary in-vitro profile, the next step is to design an in-vivo evaluation and IVIVC.

In-vivo assessment may be performed using a variety of methods, some of which are listed below: a. Clinical response; b. Blood level information; c. Blood level information; d. Nourishing study; e. Toxicology research; f. Radioactive tracer technique[31-33]

3. Research Concerning Stability

In order to guarantee the potency, clarity, authenticity, quality, and safety of the medicine as well as the IVIV release speeds that they say up to the time that it is consumed, appropriate stabilizing statistics of the drug and its dose form are required. Additionally, the extended-release drug has to be able to provide the same quantity of the medication at regular intervals, and this quantity can't alter while it's being kept. Acceleration or environmental conditions such as temperature and humidity may have an effect on the in-vitro and in-vivo release rates of the SR drug. The stabilization programming of a sustained-release product is maintained at temperature and humidity conditions that are both standard and quick. This ensures that the material can endure the conditions that it will be exposed to in the future.

4. Bioavailability Testing:

The term "bioavailability" refers to a specific medication moiety, which is often an active pharmaceutical component. This medication moiety might either be the medicine in its natural state or a metabolite, such as in the case of prodrugs. The net flow of drug-related material from the site of administration into the body is often referred to as "absorption," and the term "absorption" is commonly used to characterize this movement. The adjustment of the therapeutic dose form can be required in order to improve the absorption qualities of the medication and, as a consequence, its bioavailability. Studies of bioavailability generally compare the tested medicinal product when it is administered as a single dosage to healthy participants who are fasting. [36-38]

II. CONCLUSION

This review research focused mostly on the composition of long-lasting matrices tablets, as well as their advantages and disadvantages, and the many polymers that were used to build a technique. The previous discussion has led us to the conclusion that the matrix tablets are effective in overcoming patient compliance concerns as well as issues related to the efficiency of the dosage form. These issues are connected to the failure of traditional dosage forms to provide the necessary therapeutic response. In addition to its numerous benefits, one of the pluses is that it may either be consumed all at once or on a daily basis. Because of this, the design of the dosage form is now being optimized to produce sustained-release matrix tablets. [39-40]

REFERENCES

[1]. Gupta PK and Robinson JR. Oral controlled release delivery. Treatise on controlled drug delivery. 1992;93(2):545-555.
[2]. Jantzen GM and Robinson JR. Sustained and Controlled- Release Drug Delivery systems. Modern Pharmaceutics. 1995; 121(4): 501-502.
[3]. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone

MJ, Hadgraft J, and Robert MS. Modified Release Drug Delivery Technology, Marcel Dekker Inc., New York, 2003; 126: 996.
[4]. Gwen MJ and Joseph RR, In Banker GS and Rhodes CT, Eds. Modern Pharmaceutics, Marcel Dekker Inc. New York, 1996; 72(3): 575.
[5]. Salsa T, Veiga F and Pina ME. Oral controlled release dosage form. I. cellulose ether polymers in hydrophilic matrices. Drug Develop. Ind. Pharm. 1997; 23: 929-938.
[6]. Wani MS et al. Controlled Release system-A Review. Pharmaceutical Reviews. 2008; 6(1): 41-46.
[7]. Altaf AS, Friend DR, MASRx and COSRx Sustained-Release Technology in Rathbone MJ, Hadgraft J, Robert MS, Modified Release Drug Delivery Technology, Marcell Dekker Inc., New York, 2003. JPSBR: Volume 1, Issue 3: Nov Dec 2011 (143-151) Patel H. 151
[8]. Vidyadhara S, Rao PR, Prasad JA. Formulation And Evaluation Of Propranolol Hydrochloride Oral Controlled Release Matrix Tablets. Indian J.Pharm Sci, 2004; 66: 188-192.
[9]. Reddy KR, Mutalik S, Reddy S. Once-daily sustained release matrix tablets of Nicorandil: Formulation and in vitro evaluation,AAPS Pharm. Sci. Tech.,2003; 4: 1-9.
[10]. Mohammed AD, James LF, Michael HR, John EH, Rajabi-Siahboomi AR. Release of Propranolol hydrochloride from matrix tablets containing sodium carboxy methylcellulose and Hydroxy propyl methyl cellulose. Phar. Dev. Tech.,1999; 4: 313-324.
[11]. Lee BJ, Ryu SG, Cui JH. Formulation and release characteristics of hydroxypropyl methylcellulose matrix tablet containing melatonin. Drug Dev. Ind.Pharm.,1999; 25: 493-501.
[12]. Gwen MJ, Joseph RR, In Banker GS and Rhodes CT, Eds., Modern Pharmaceutics, 3rd Edn, Vol. 72, Marcel Dekker Inc. New York, 1996: 575.
[13]. 13.Borguist P, Korner A, Larsson A: A model for the drug release from a polymeric matrix tablets-effect of swelling and dissolution. J Controlled Release 2006; 113: 216-225.
[14]. Siepmann J, Peppas NA. Modeling of drug release from delivery systems based on hydroxypropyl methylcellulose (HPMC). Adv Drug Dev Rev 2001; 48:139-157.
[15]. http://dissertations.ub.rug.nl/Files/faculties/sc i ence/2005/r.steendam/c2.pdf(5Aug, 2006).
[16]. Reza MS, Quadir MA, Haider SS. Comparative evaluation of plastic, hydrophobic and hydrophilic polymers as matrices for controlled release drug delivery. J Pharm Pharmaceut Sci 2003; 6 (2): 282-291.
[17]. Brazel CS, Peppas NA. Dimensionless analysis of swelling of hydrophilic glassy polymers with subsequent drug release from relaxing structures. Biomaterials 1999 Apr; 20 (8): 721- 732.
[18]. Brazel CS, Peppas NA. Modeling of drug release from swellable polymers. Eur J Pharm Biopharm 2000 Jan; 49 (1): 47-58.
[19]. http://dissertations.ub.rug.nl/Files/faculties/sc ie nce/2005/r.steendam/c2.pdf(5Aug, 2006).
[20]. Hariharan M, Wheatley TA, Price JC. Controlled release tablet matrices from carrageenans: compression and dissolution studies. Pharm Dev Technol 1997; 2(4): 383–393.
[21]. Takka S, Rajbhandari S, Sakr A. Effect of anionic polymers on the release of propranolol hydrochloride from matrix tablets. Eur J Pharm Biopharm 2001; 52:75-82.
[22]. Alderman DA. Review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage form. Int. J. Pharm. Technol. Prod. Mfr. 1984; 5: 1-9.
[23]. Melia CD. Hydrophilic matrix sustained release systems 395- based on polysaccharide carriers. Crit. Rev. Ther. Drug Carrier Sys. 1991; 8(4): 421.
[24]. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494.
[25]. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, Third Edition, Revised and Expanded, Drugs and the Pharmaceutical Sciences, vol 72, Marcell Dekker, Inc. New York, 1995: 575-609.
[26]. Alford N Martin, Patrick J. Sinko. Martin's Physical pharmacy and pharmaceutical sciences, 2006.
[27]. L. Lachman, HA Lieberman, Joseph L Kanig. The theory and practice of Industrial pharmacy, Verghesh publishing house, 3rd edition, 1990; 346.
[28]. mamidala RK, Ramana V, sandeep G, "Factors influencing the design and

performance of oral, sustained /controlled Release dosage forms" UPSN,2009,S83-S86.
[29]. Leon S, Susanna W, Andrew BC , "Applied Biopharmaceutics and Pharmacokinetics", 5th edition McGraw-Hill's Access Pharmacy, 2004, 17.1-17.9.
[30]. Sayed I. Abdel-Rahman, Gamal MM, El-Badry M, Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets, Saudi Pharmaceutical Journal ,2009 ; 17: 283-288.
[31]. Chandran S, Laila FA and Mantha N, Design and evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics, Indian Journal of Pharmaceutical Sciences, September-October 2008.
[32]. Gothi GD, Parinh BN, Patel TD, Prajapati ST, Patel DM, Patel CN, Journal of Global Pharma Technology, 2010; 2(2): 69-74.
[33]. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494.
[34]. Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th edition, 1999: 169-171.
[35]. Muzib Y.Indira, Padma Sree.Kurri: Formulation and evaluation of gum olibanumbased sustained release matrix tablets of Ambroxol hydrochloride. International Journal of Pharmacy and Pharmaceutical Sciences 2011; 3(2): 195-199.
[36]. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Ist ed. vallabh prakashan, 2002:156-189.
[37]. Brahmankar HA, Jaiswal SB. Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337.
[38]. Venkatraman S, Davar A, Chester A, Kleiner L, Wise DL. An overview of controlled release systems, Handbook of Pharmaceutical Controlled Release Technology, New York, Marcel Dekker, Inc.,2000, 431-465.
[39]. Sriwongjanya M and Bodmeier R. Entrapment of drug loaded ion exchange particles within polymeric microparticles. Int. J. Pharm. 1988; 48: 217-222.
[40]. Brahmankar HA, Jaiswal SB, Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337.